OBJECTIVES: to analyze the savings derived from the centralized preparation of intravenous admixtures and intravitreal drugs from the pharmacy service of a 1419-bed hospital.

METHODS: Retrospective longitudinal study during 4 years: 2015-2018. Data source: MIV preparation database, pharmacoeconomic management program, and Pharmacy Department activity and quality indicators. We have considered the savings generated by the centralized preparation of drugs with high economic impact, considering a 100% use of the vials due to the grouping of patients. Inclusion criteria: drugs of high economic impact prepared centrally in Pharmacy Department: aminoglycosides, liposomal and lipid amphotericin B, anidulafungin, caspofungin, daptomycin, nonspecific immunoglobulin, infliximab, tocilizumab, thymoglobulin, vancomycin and voriconazole, agalsidase-beta, belimumab, mepolizumab, reslizumab, ranibizumab, aflibercet Exclusion criteria: cytostatics, immunosuppressants, antivirals. Descriptive statistics of means and percentages are applied.

RESULTS:Number of prepared intravenous admixtures by year 2015: 28,168; 2016: 31,673; 2017: 28,115; 2018: 31,289. The most frequent were aminoglycosides and vancomycin derived from the recommendation after monitoring plasma levels: 56% followed by daptomycin 12.8%, voriconazole 6.2% caspofungin 5.5% infliximab 4.2% and anidulafungin 4.3% Savings achieved: 2015: 2,097,944€; 2016: 2,832,288€; 2017: 3,123,537€; 2018 2,491,674 €. The drugs where greater efficiency was observed were the intravitreal preparations 8,348,911 (79%), by centralizing the preparation in the pharmacy service, each vial provides doses for several patients. In these 4 years, the savings obtained represent 3.01% of total spending on medicines.

CONCLUSIONS: The savings generated in the preparation area of intravenous admixtures indicate the high profitability of the Pharmacy Department, especially when it comes to drugs with high economic impact in which the dose of the patient does not adjust to the content of the vial.